Technical Data
Synaptophysin labels normal neuroendocrine cells of human adrenal medulla, carotid body, skin, pituitary gland, thyroid, lung, pancreas, gastrointestinal mucosa, Paneth’s cells in the gastrointestinal tract and of gastric parietal cells. Neurons in the brain, spinal cord, and retina are also labeled. Anti-synaptophysin reacts with neuroendocrine neoplasms of neural as well as epithelial types e.g. neuroblastomas, ganglioneuroblastomas. ganglioneuromas, pheo-chromocytomas, chromaffin, and non-chromaffin paragangliomas. Of the epithelial types include pituitary adenomas, islet cell neoplasms, medullathyroid carcinomas, parathyroid adenomas, carcinoids of the bronchopulmonary and gastro-intestinal tracts and neuroendocrine carcinomas of the skin. In combination with anti-chromogranin A and anti-NSE, anti-synaptophysin is very useful in the identification of normal neuroendocrine cells and neuroendocrine neoplasms.

Suitable for use in Immunohistochemistry, ELISA and Western Blot. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry (Paraffin): 1:25. Requires heat induced antigen retrieval using citrate buffer pH 6.0.
Western Blot: 1:500
Optimal working dilutions to be determined by researcher.

Recommended Positive Control Tissue:

NSO Myeloma cells with B cells from Balb/c mice.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
200ug-20°CBlue IceHumanMouse
Crude human synaptic immunoprecipitate
Supplied as a liquid in PBS, 0.09% sodium azide
Recognizes human synaptophysin, also known as Major synaptic vesicle protein p38.. Species Crossreactivity: hamster, rat and marmoset
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Honer, W.G. et al. (1994) Hippocampal synaptic pathology in patients with temporal lobe epilepsy. Acta Neuropathol. 87: 202-210. 2. Honer, W.G. et al. (1992) Regional synaptic pathology in Alzheimer's disease. Neurobiol. Aging. 13: 375-382. 3. Honer, W.G. et al. (1993) Human synaptic proteins with a heterogeneous distribution in cerebellum and visual cortex. Brain Res. 609: 9-20. 4. Honer, W.G. et al. (1992) Characterization of a synaptic antigen of interest in neuropsychiatric illness. Biol. Psychiatry 31: 147-158. 5. Honer, W.G. et al. (1989) Monoclonal antibodies to study the brain in schizophrenia. Brain Res. 500: 379-383. 6. Masliah, E. et al. (1994) Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus. Acta Neuropathol. 87: 135-142. 7. Simpson, I.A. et al. (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol. 35: 546-551. 8. Wakabayashi, K. et al. (1994) Synapse alterations in the hippocampalentorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Research 667: 24-32. 9. Dickson, D.W. et al. (1994) Hippocampal sclerosis: a common pathological feature of dementia in very old (> or = 80 years of age) humans. Acta Neuropathologica 88: 212-221.10. Dickson, D.W. et al. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-98.11. Vitry, S. et al. (2010) Enhanced degradation of synaptophysin by the proteasome in mucopolysaccharidosis type IIIB. Mol Cell Neurosci. 41: 8-18.